Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype
Name
Anderson_Genome editing.pdf
Size
844.29 KB
Format
Adobe PDF
Checksum (MD5)
7a744df8db54348cc362dbc17a11a05e
Author(s)
Yin, Hao
Xue, Wen
Chen, Sidi
Benedetti, Eric
Grompe, Markus
Kotelianski, Victor E.
Bogorad, Roman
Sharp, Phillip A.
Anderson, Daniel Griffith
Jacks, Tyler E
Date Issued
March 2014
Journal
Nature Biotechnology
Publisher
Nature Publishing Group
Citation
Yin, Hao, Wen Xue, Sidi Chen, Roman L Bogorad, Eric Benedetti, Markus Grompe, Victor Koteliansky, Phillip A Sharp, Tyler Jacks, and Daniel G Anderson. “Genome Editing with Cas9 in Adult Mice Corrects a Disease Mutation and Phenotype.” Nature Biotechnology 32, no. 6 (March 30, 2014): 551–553.
Version
Author's final manuscript
Abstract
We demonstrate CRISPR-Cas9–mediated correction of a Fah mutation in hepatocytes in a mouse model of the human disease hereditary tyrosinemia. Delivery of components of the CRISPR-Cas9 system by hydrodynamic injection resulted in initial expression of the wild-type Fah protein in ~1/250 liver cells. Expansion of Fah-positive hepatocytes rescued the body weight loss phenotype. Our study indicates that CRISPR-Cas9–mediated genome editing is possible in adult animals and has potential for correction of human genetic diseases.
MIT Department
Massachusetts Institute of Technology. Institute for Medical Engineering & Science
Harvard University--MIT Division of Health Sciences and Technology
Massachusetts Institute of Technology. Department of Biology
Massachusetts Institute of Technology. Department of Chemical Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1038/nbt.2884
